Company Overview and News

 
NZ shares fall most across Asia; Z Energy still under pressure

2018-10-19 nzherald.co.nz
New Zealand shares fell the most across Asia as Z Energy led the market lower for another day amid rising oil prices, growing competition and the threat of increased regulation.
CEN PGC AIR FCREY ZNRGF NZTCF RYM ACKDF ANZFY AUKNY AIZ COENF SKT ZNZ SYKWF CEN SKKTY AIA FBU RHCGF SPKKY NZTCY EBOSY SPK ZEL FRCEF EBO COENY KWIPF EBOSF AIA FBU ANZLY RYHTY ANZFF MEZ EBO

 
NZ shares fall as Meridian faces declining hydro storage

2018-10-16 nzherald.co.nz
New Zealand shares fell for a second day with Meridian Energy lower as the power company confronts dry conditions, and exporters Comvita and Fisher & Paykel Healthcare faced a stronger kiwi dollar.
RHCGF SPKKY EBOSY NZTCY SPK NZTCF RYM EBO SKT GNE AOTUF EBOSF SYKWF PPSHY RYHTY VTHPF SKKTY GNE MEZ GEL EBO

 
NZ shares fall as A2 Milk extends decline

2018-09-27 nzherald.co.nz
New Zealand shares fell as A2 Milk Co extended its decline since its chief executive sold down her holding. Rising bond yields also dimmed the lustre of property stocks.
AIA FBU FCREY SPKKY EBOSY NZTCY SPK NZTCF ACKDF FRCEF EBO AUKNY KWIPF AOTUF EBOSF SKC AIA FBU THL VTHPF SKLUY SKL MEZ EBO

 
EBOS Group, Ltd. ADR 2018 Q4 - Results - Earnings Call Slides

2018-08-23 seekingalpha
The following slide deck was published by EBOS Group, Ltd. ADR in conjunction with their 2018 Q4 earnings call.
EBOSF EBOSY EBO EBO

 
Ebos profit grows to $272 million

2018-08-22 nzherald.co.nz
Ebos Group boosted annual earnings in line with its forecast even though revenue fell, as the pharmaceutical and animal health products company increased margins and benefited from acquisitions.
EBOSF EBOSY EBO EBO

 
NZ shares lift as Synlait rallies on A2 stake lift

2018-08-03 nzherald.co.nz
New Zealand shares gained, led higher by Synlait Milk as A2 lifted its stake in the company while Freightways and Ebos fell.
KTHDY BGR EBOSF THL PPSHY EBOSY SNZ KMD EBO EBO SML KMD

 
Freightways, Sky TV lead NZ shares gain

2018-07-31 nzherald.co.nz
New Zealand shares gained, led higher by Freightways and Sky Network Television as the market remains quiet ahead of earnings season.
CEN ZNRGF KMD COENF SKT ZNZ GNE SYKWF SKC CEN SKKTY FGHRY KMD GEL KTHDY EBOSY FLT ZEL EBO COENY KWIPF EBOSF EVO GNE GTK EBO

9
Dispensing disruption: Are pharmacies ready for digital rivals?

2018-07-06 theage.com.au
When Amazon announced its purchase last week of online pharmacy PillPack, which packages and delivers pre-sorted doses of prescribed drugs direct to consumers’ homes, major US-based pharmacies from CVS Health to Walgreens saw their share prices fall about 10 per cent.
EBOSF RMYHY API RHC EBOSY CVS EBO RMSYF EBO

9
Dispensing disruption: Are pharmacies ready for digital rivals?

2018-07-06 smh.com.au
When Amazon announced its purchase last week of online pharmacy PillPack, which packages and delivers pre-sorted doses of prescribed drugs direct to consumers’ homes, major US-based pharmacies from CVS Health to Walgreens saw their share prices fall about 10 per cent.
EBOSF RMYHY API RHC EBOSY CVS EBO RMSYF EBO

 
ASX lifts for the week despite the looming trade war

2018-07-06 theage.com.au
The Australian sharemarket has ended the week with a fresh 10-1/2-year high on Friday, despite the US going ahead with tariffs that could potentially begin an all-out trade war with China.
DB API EBOSY EBO RSG EBOSF RMGGY RMGGF MS EBO

 
ASX lifts for the week despite the looming trade war

2018-07-06 smh.com.au
The Australian sharemarket has ended the week with a fresh 10-1/2-year high on Friday, despite the US going ahead with tariffs that could potentially begin an all-out trade war with China.
DB API EBOSY EBO RSG EBOSF RMGGY RMGGF MS EBO

 
NZ shares up; Auckland Airport leads gains

2018-07-05 nzherald.co.nz
New Zealand shares rose in light trading, led higher by Auckland International Airport and Westpac Banking Corp, with Heartland Bank and Fletcher Building softening.
AIA FBU WBC FCREY EBOSY WEBNF WBK ACKDF FRCEF EBO AUKNY EBOSF AIA WBC FBU SKLUY SKL EBO

2
Australian shares advance on strength of major banks

2018-07-03 theage.com.au
The Australian sharemarket has recorded only its second advance in the last eight sessions despite a broad retreat of commodity prices overnight.
PILBF RIO DB BLT RIO IAG BEPTF RTPPF GALXF RTNTF MS TWE SML IAUGY PLS TSRYY BHPBF EBOSY EBO BCHEY BPT EBOSF TSRYF GXY IAUGF BHP RIO BBL BHP BHPLF EBO

2
Australian shares advance on strength of major banks

2018-07-03 smh.com.au
The Australian sharemarket has recorded only its second advance in the last eight sessions despite a broad retreat of commodity prices overnight.
PILBF RIO DB BLT RIO IAG BEPTF RTPPF GALXF RTNTF MS TWE SML IAUGY PLS TSRYY BHPBF EBOSY EBO BCHEY BPT EBOSF TSRYF GXY IAUGF BHP RIO BBL BHP BHPLF EBO

 
NZX 50 rises 1.2% to new record on Ebos Group gains

2018-07-03 nzherald.co.nz
New Zealand shares jumped to a record with Ebos Group hitting a fresh high while A2 Milk Co and Synlait Milk gained on news they plan to extend their supply contract.
EBOSF NZTCY SPKKY OHE EBOSY SPK NZTCF EBO FTRRF EBO SML

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: 278727102